For 18 years, Truffle Capital has been creating and financing to success radical and disruptive innovations in two fields of expertise, Life Sciences and Information Technologies. These creations revolutionize their sectors and will become the tomorrow’s leaders.
Truffle Capital is the only European Fund to support its innovations from creation to commercial success.
Truffle Capital works closely with the world's best 50 universities to select and transform their most significant inventions into major technological innovations, novel medical devices and effective drug treatments.
In terms of Information technologies, Truffle Capital has focused in FinTechs since 2014. Thanks to its team of dedicated experts, Truffle is able to select products & services with underlying complex technologies (deep tech).
Holistick raises $5M to boost preclinical development of PFO closure device
Truffle Capital reports outstanding 2020 stock market performance for its listed BioMedTech portfolio companies
Three companies founded or co-founded by Truffle represent 30% of the total valuation of the highest BioMedTech market caps of Euronext Paris...
Discussion of Abivax Clinical Program involving Covid-19, Ulcerative Colitis, Crohn’s Disease and more
Hartmut Ehrlich and Philippe Pouletty discuss Abivax Pipeline of Clinical Programs involving Covid-19, Ulcerative Colitis, Crohn’s Disease...
Centers for Medicare & Medicaid Services (CMS) grant transitional pass-through (TPT) payment for Stryker's SpineJack® System
CMS announced the SpineJack implantable fracture reduction system qualified for the TPT payment as part of the 2021 Medicare Payment System.
Great article about Abivax : what makes it a unique candidate to treat Covid-19
In addition to its exciting results in ulcerative colitis...
Carbios strengthens its position as a reference shareholder in its subsidiary Carbiolice
The company created by Truffle acquired Limagrain Ingredients' position in Carbiolice, thus increasing its shareholding from 52% to 70%.